Statin Use and Knee Osteoarthritis Outcome Measures according to the Presence of Heberden Nodes: Results from the Osteoarthritis Initiative
Statin Use and Knee Osteoarthritis Outcome Measures according to the Presence of Heberden Nodes: Results from the Osteoarthritis Initiative
复制标题
DOI：
10.1148/radiol.2019190557
复制
发表时间：
2019-11-01
期刊：
影响因子：
19.7
通讯作者：
Demehri, Shadpour
中科院分区：
文献类型：
--
作者：
Haj-Mirzaian, Arya;Mohajer, Bahram;Demehri, Shadpour
背景资料：他汀类药物对膝关节骨关节炎（OA）放射学结局的确切作用以及OA患者作为他汀类药物潜在应答者的特征尚不清楚。目的：评价他汀类药物使用对放射学膝关节OA发生率的影响根据Heberden淋巴结的存在定义的淋巴结OA状态（Keller-Lawrence分级>= 2）和关节间隙狭窄（JSN）的进展（HN）。材料和方法：机构审查委员会批准了这项符合HIPAA的方案，并且所有参与者都给予了知情同意。骨关节炎倡议（OAI）队列始于2004年，目前正在进行（https：clinicaltrials.gov标识符，NCT 00080171），用于对前瞻性收集的数据进行纵向1：1倾向评分匹配回顾性分析。根据基线体格检查时是否存在HN，将参与者分为HN阳性或HN阴性结果。在每个队列中，使用符合方案和新用户设计来匹配他汀类药物启动者（报告
Background: The exact contribution of statins to knee osteoarthritis (OA) radiographic outcomes and the characteristics of patients with OA as potential responders to statins remain unclear.Purpose: To evaluate the effect of statin use on the incidence of radiographic knee OA (development of Kellgren-Lawrence grade >= 2) and progression of joint space narrowing (JSN) according to the nodal OA status defined according to the presence of Heberden nodes (HNs).Materials and Methods: Institutional review boards approved this HIPAA-compliant protocol, and all participants gave informed consent. The Osteoarthritis Initiative (OAI) cohort, which began in 2004 and is ongoing (https://clinicaltrials.gov identifier, NCT00080171), was used to conduct a longitudinal 1:1 propensity score-matched retrospective analysis of prospectively collected data. Participants were classified as having HN-positive or HN-negative findings according to the presence of HNs at baseline physical examination. In each cohort, per-protocol and new-user design were used to match statin initiators (participants who reported